Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT01200758
- Locations
- 🇨🇴
Fundacion Cardioinfantil, Bogota, Colombia
🇲🇽Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico
🇨🇴Centro Medico Imbanaco, Cali, Colombia
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 6
- Registration Number
- NCT01186328
- Locations
- 🇦🇺
Sydney Children's Hospital, Sydney, Australia
🇺🇸St. Jude, Memphis, Tennessee, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 226
- Registration Number
- NCT01148446
- Locations
- 🇮🇹
Ospedale San Sebastiano, Correggio (RE), Italy
🇮🇹Istituto Vito Fazzi, Lecce, Italy
🇮🇹S.C. di Ematologia, Spedali Civili, Brescia, Italy
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
- Conditions
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 479
- Registration Number
- NCT01096368
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT01040871
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01014767
- Locations
- 🇳🇿
Christchurch Hospital, Christchurch, New Zealand
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇭🇺Semmelweis University, Budapest, Hungary
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 50
- Registration Number
- NCT01009970
- Locations
- 🇮🇹
Ospedale Sant'Eugenio, Roma, Italy
🇮🇹Ospedale Riuniti, Trieste, Italy
🇮🇹Ospedale SS Antonio Biagio e Cesare Arrigo, Alessandria, Italy
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 14
- Registration Number
- NCT01004991
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 51
- Registration Number
- NCT01004497
- Locations
- 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT01000285
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of Miami Hospital/Sylvester, Miami, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.